Form 10-Q ALNYLAM PHARMACEUTICALS, For: Jun 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Raymond James Upgrades Alnylam Pharmaceuticals (ALNY) to Strong Buy
August 3, 2026 7:20 AM EDTRaymond James analyst Martin Auster upgraded Alnylam Pharmaceuticals (NASDAQ: ALNY) from Outperform to Strong Buy with a price target of $420.00.
The analyst comments "ALNY shares are -35% since early July on a series of events that have called LT growth potential for... More
